Passa al contenuto
Merck
Tutte le immagini(1)

Key Documents

Altri documenti

C-130

Supelco

Cortisone solution

100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C21H28O5
Numero CAS:
53-06-5
Peso molecolare:
360.44
Numero CE:
200-659-6
Codice UNSPSC:
41116107
NACRES:
NA.24

Grado

certified reference material

Forma fisica

liquid

Caratteristiche

(Snap-N-Spike®)

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

Concentrazione

100 μg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing
clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

InChI

1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h9,14-15,18,22,26H,3-8,10-11H2,1-2H3/t14-,15-,18+,19-,20-,21-/m0/s1
MFYSYFVPBJMHGN-ZPOLXVRWSA-N

Descrizione generale

Cortisone is a corticosteroid produced in the adrenal glands. Cortisone is administered for short term pain relief and to reduce swelling from inflammation. This Certified Spiking Solution® is applicable in LC-MS/MS applications for endocrinology, clinical chemistry and neonatal screening.

Applicazioni


  • Measurement of free urinary cortisol and cortisone: A study demonstrated the use of cortisone solutions in a method for the precise measurement of free urinary cortisol and cortisone using liquid chromatography and tandem mass spectrometry, crucial for diagnosing and managing endocrine disorders (Vieira et al., 2005).


Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

C-106

Cortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-113

Cortisol-D4 (9,11,12, 12-D4) solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-117

Corticosterone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-061

11-Deoxycortisol solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-062

21-Deoxycortisol solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-076

21-Deoxycortisol-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-078

11-Deoxycortisol-D5 (2,2,4,6,6-D5), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

D-085

Dexamethasone solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-096

17α-Hydroxyprogesterone-d8 (2,2,4,6,6,21,21,21-d8), 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-100

17α-Hydroxyprogesterone-2,3,4-13C3 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

P-069

Progesterone solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

P-070

Progesterone-D9 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

H-151

6alpha-Hydroxyhydrocortisone solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

C-160

Cortisone-13C3 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

C-159

Corticosterone-13C3 solution, 10 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

P-124

Prednisone-13C3 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

K Parsch et al.
Der Orthopade, 24(1), 65-72 (1995-02-01)
Seventy-one children and adolescents with unicameral bone cysts were treated between 1982 and 1992. Fifty-one percent were in the proximal humerus, 34% in the femur, 10% in the tibia, and only 5% in other sites. Until 1986 biopsies were routinely
P M Stewart et al.
Hormone research, 56 Suppl 1, 1-6 (2002-01-12)
In peripheral tissues, corticosteroid hormone action is determined, in part, through the activity of 11beta-hydroxysteroid dehydrogenases (11beta-HSD), two isozymes of which interconvert hormonally active cortisol (F) and inactive cortisone (E). 11beta-HSD type 2 (11beta-HSD2) inactivates F to E in the
B U Ihle
Anaesthesia and intensive care, 29(2), 155-162 (2001-04-21)
The use of steroids as an adjunct to antimicrobial therapy has been controversial for many decades. Recent reports of the use of steroids in supraphysiological rather than in "industrial" doses in patients with sustained circulatory instability has re-ignited the debate.
A Matucci et al.
Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna, 11(3), 187-195 (1996-07-01)
There is general agreement on the inflammatory pathogenesis of bronchial asthma: an accumulation of activated eosinophils, degranulated mast cells, T lymphocytes and in very severe forms, granulocytes has constantly been found in the bronchial mucosa. In allergic bronchial asthma, inflammation
I Uttner et al.
Der Nervenarzt, 77(6), 647-648 (2005-11-12)
Treatment with high-dose corticosteroids over 3-5 days reduces the duration and severity of relapses in patients with multiple sclerosis. Since the benefit of this treatment appears to be dose-dependent, application of ultrahigh steroid doses becomes important. On the other hand
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.